Protection against the electromagnetic field intolerance syndrome
Clinical study shows Immun’Âge® helps improve symptoms for EHS (Electrohypersensitive) patients
The electromagnetic field intolerance syndrome (EMFIS) is an extreme reaction to low-level exposure to ElectroMagnetic Fields (EMFs) emitted by wireless telecommunication technologies.
In 2017, Dr. Belpomme worked on a clinical study with ORI to evaluate the beneficial effects of the fermented papaya preparation (FPP®) on EHS patients.
Overall, clinical improvements were obtained in 50-60% of cases, showing a diminution of oxidative stress and inflammatory phenomena, as well as a normalization of brain oxygenation.
For these patients, this resulted in fewer and milder clinical symptoms such as headaches, fatigue, tachycardia episodes, insomnia, and attention deficit to name a few.
“We demonstrated that by stimulating the antioxidant defense system, FPP® can help fight the oxidative stress caused by electromagnetic waves, and reduce intolerance to their harmful effects.”
Professor of Oncology at the Paris Necker Hospital
US patent for EHS
Based on this study, Osato International was granted in 2021 the US patent N° US 10.993.980 B2 for “METHOD FOR TREATING ELECTROHYPERSENSITIVITY WITH A FERMENTED PAPAYA PREPARATION”
How to use Immun'Âge for EHS
Action: Diminution of oxidative stress and inflammatory phenomenon and normalisation of brain oxygenation.
Result: Diminution of number and severity of clinical symptoms (headache, fatigue, tachycardia episodes, insomnia, attention deficit).
Dosage: The study shows that best results are obtained after 6 months of supplementation.
> Months 1 to 3: 9g/day (3g-packet x 3)
> Months 4 to 6: 6g/day (3g-packet x 2)
> Month 7: Pause supplementation
> Month 8 +: Supplement according to symptoms
Phase I-II study testing the therapeutic effect and stimulating properties of antioxidant defences to patients suffering of Electromagnetic Fields Intolerance Syndrome. D. BELPOMME & Co | Functional Foods in Health and Disease 2018; 8(2): 122-144
US Patent No.US10993980B2 – “Method for Treating Electrohypersensitivity with FPP®"